STAT April 7, 2024
Lizzy Lawrence

A controversial heart pump from Abiomed reduced the number of deaths in severe heart attack patients, according to a highly anticipated randomized trial presented at the American College of Cardiology conference and published in the New England Journal of Medicine on Sunday.

The trial, which took 10 years to enroll, followed 355 patients for 180 days in Denmark, Germany, and the United Kingdom who came into the hospital with a heart attack and dangerously low blood flow, known as cardiogenic shock. Half...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, Conferences / Podcast, Medical Devices, Patient / Consumer, Provider, Trends
GE HealthCare Expands Cardiac AI Coaching to Hand-Held Ultrasound Scanner
Orthobond Receives FDA De Novo Approval for Antibacterial Technology
The Top 25 Medical Device Executives of 2024
New regulations to help turn tide on health care cyberattacks
Digital Health Intelligence Market Analysis: Medical Device Cyber Security

Share This Article